TMCnet News

Frazier Healthcare Names Veteran Pharmaceutical Executive Richard E. Maroun, Esq., as an Operating Executive
[April 01, 2015]

Frazier Healthcare Names Veteran Pharmaceutical Executive Richard E. Maroun, Esq., as an Operating Executive


Frazier Healthcare, a leading provider of growth capital to healthcare companies, announced today that Richard E. Maroun, Esq., has joined the firm as an Operating Executive on the Growth Buyout team. Mr. Maroun joins a group of industry-leading Frazier Operating Partners and Executives that guide portfolio companies to double-digit growth and operational excellence. Mr. Maroun, a seasoned pharmaceutical executive, has held numerous legal, financial and administrative positions in some of healthcare's fastest-growing companies.

"Rick brings a great deal of expertise and wisdom to Frazier because he intimately understands the challenges that our companies face every day," said Alan Frazier, Founder & General Partner at Frazier Healthcare. "He is acknowledged in the industry as a leader who can partner with company management. He brings great creativity to the toughest challenges, can help companies improve marketplace execution, and ultimately bring transformative healthcare solutions to people worldwide."

Most recently, Mr. Maroun was Senior Vice President and General Counsel of Aptalis Pharma, where he helped engineer the Aptalis acquisition by Forest Laboratories for $2.9 billion. Previously, he joined the Frazier team in the creation of Packaging Coordiators, after a buyout of the pharmaceutical packaging business from Catalent Corporation. He has served in numerous senior roles for APP Pharmaceuticals -- as Executive Vice President, Chief Administrative Officer, General Counsel, and Business Development Officer -- where he secured the sale of the company to Fresenius SE in a transaction worth $3.7 billion. Mr. Maroun has also served in senior positions with Abraxis BioScience and American BioScience. He has worked with major financial organizations and independent law firms, and has held both legal and financial positions with companies including Merrill Lynch, Deloitte (News - Alert) & Touche, and McDonough, Holland & Allen.



"Throughout my career, I've had the opportunity to work with many talented people in the growth equity and venture capital industry," said Mr. Maroun. "I have deep respect not only for Frazier's investment acumen, but for their desire to develop and enrich each company they invest in. Their commitment is resolute and, in my experience, companies need partners that will invest with long-term conviction and brave new challenges and opportunities."

About Frazier Healthcare


Founded in 1991, Frazier Healthcare is a leading provider of venture and growth buyout capital to healthcare companies. With over $2 billion under management, Frazier Healthcare has invested in more than 150 companies across the entire development spectrum. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies. The firm's Growth Buyout team focuses on investments in healthcare services, pharmaceutical services, healthcare information technology, products, supplies, and specialty distribution. The firm's Life Sciences team focuses on investments in development-stage therapeutics, specialty pharmaceuticals, and related areas that are addressing unmet medical needs through innovation.

For more information about Frazier Healthcare, visit the company's website at www.frazierhealthcare.com.


[ Back To TMCnet.com's Homepage ]